Newsylist real-time news trend intelligence
▲ Peaking Health

Seattle breakthrough offers Spokane boy relief from rare hunger condition

A new FDA-approved therapy, setmelanotide, is providing relief for patients suffering from hypothalamic obesity caused by brain injury.

5sources
5articles
3velocity
+0%since first seen
6h agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

3210Jul 21 05:29Jul 21 13:29 UTC

The brief

The FDA has approved a new therapy, setmelanotide, to treat obesity resulting from brain injury. A boy from Spokane has utilized this treatment to find relief from a rare condition of constant hunger caused by brain damage.

Coverage from The ASCO Post, the limbic, and NR Times emphasizes that the drug targets acquired hypothalamic obesity, specifically in patients with brain tumors. Reports from KREM and The Spokesman-Review highlight the personal impact on the Spokane patient, who is described as being able to get "back to living life.

Attention is now on trial results showing setmelanotide's ability to cut BMI in patients with hypothalamic obesity.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6h ago.

Quick answers

What is the name of the approved therapy?

The therapy is called setmelanotide.

What specific condition does this treatment address?

It treats hypothalamic obesity caused by brain injury or brain tumors.

What result was noted in the clinical trial?

According to the limbic, the trial showed that setmelanotide cuts BMI.

Coverage (5)

People, places & organizations

Topics

Related trends